Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500.

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...

providing valuable ballast to Gilead's portfolio. Earlier this year, Gilead acquired the liver disease-focused biotech Cyma Bay in a deal worth ~$4.3bn, giving it access to seladelpar, now ...

Gilead’s oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified the company’s overall business. However, the Cell Therapy franchise ...

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseases. While the drug candidates ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent ...

While the Gilead pipeline has promise, the HIV portfolio of drugs has generated the most robust results. It was determined to exit the position as the pipeline timeline has been pushed out.

In addition to antiviral therapies for HIV and HCV, Gilead's oncology portfolio should also be mentioned, but only for the sake of completeness. Its CAR T-cell therapies Tecartus and Yescarta ...

Through this agreement, Gilead will gain access to Tubulis ... “As we expand our oncology portfolio to address the greatest gaps in care, accessing novel technologies is critical to advancing ...